Ubs Asset Management Americas Inc Cara Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$8.88 - $12.77 $4,555 - $6,551	513 Added 0.61%	84,378 $906,000
Q3 2022 Nov 14, 2022	BUY	$8.24 - $12.56 $230,275 - $351,001	27,946 Added 49.98%	83,865 $784,000
Q3 2021 Nov 15, 2021	SELL	$11.55 - $16.06 $55,717 - $77,473	-4,824 Reduced 7.94%	55,919 $863,000
Q2 2021 Aug 16, 2021	BUY	$12.38 - $29.19 $1,943 - $4,582	157 Added 0.26%	60,743 $866,000
Q1 2021 May 14, 2021	BUY	$15.07 - $21.71 $15,175 - $21,861	1,007 Added 1.69%	60,586 $1.32 Million
Q3 2020 Nov 13, 2020	BUY	$12.34 - $17.92 $304,378 - $442,014	24,666 Added 70.65%	59,579 $757,000
Q2 2020 Aug 14, 2020	BUY	$12.39 - $17.33 $39,449 - $55,178	3,184 Added 10.03%	34,913 $597,000
Q1 2020 May 15, 2020	SELL	$9.12 - $17.78 $18,559 - $36,182	-2,035 Reduced 6.03%	31,729 $419,000
Q4 2019 Feb 14, 2020	BUY	$16.11 - $25.98 $27,499 - $44,347	1,707 Added 5.32%	33,764 $543,000
Q3 2019 Nov 14, 2019	BUY	$18.28 - $26.91 $281,457 - $414,333	15,397 Added 92.42%	32,057 $586,000
Q2 2019 Aug 15, 2019	SELL	$17.68 - $21.57 $211,081 - $257,524	-11,939 Reduced 41.75%	16,660 $0
Q1 2019 May 14, 2019	BUY	$14.41 - $19.64 $226,395 - $308,564	15,711 Added 121.9%	28,599 $0
Q4 2018 Feb 13, 2019	SELL	$12.45 - $23.47 $102,239 - $192,735	-8,212 Reduced 38.92%	12,888 $167,000
Q2 2018 Aug 14, 2018	BUY	$11.6 - $19.27 $244,760 - $406,597	21,100 New	21,100 $0
Q4 2017 Feb 09, 2018	SELL	$11.86 - $14.08 $1.69 Million - $2.01 Million	-142,614 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$12.6 - $16.34 $1.8 Million - $2.33 Million	142,614	142,614 $0

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $247M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.